Last updated: April 5, 2018
Sponsor: Hospital Authority, Hong Kong
Overall Status: Trial Status Unknown
Phase
2/3
Condition
Sarcopenia
Polymyositis (Inflammatory Muscle Disease)
Treatment
N/AClinical Study ID
NCT03496389
Gabapentin ACLR
Ages 18-50 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Age 18-50
Unilateral isolated ACL tear for primary ACLR confirmed clinically and radiologically
No concomitant ligamentous, meniscal or chondral injuries.
Exclusion
Exclusion Criteria:
Concomitant multiple ligament injuries including posterior cruciate ligament, medialcollateral ligament ligament, or lateral collateral ligament
Concomitant meniscal injuries
Concomitant chondral injuries
preoperative radiographic signs of arthritis
Revision ACL surgery
Contralateral knee with
Medical co-morbidities including Diabetes Mellitus, chronic renal failure
Documented hypersensitivity to Gabapentin
History of epilepsy
History of depression
Non-compliance to rehabilitation protocol.
Study Design
Total Participants: 30
Study Start date:
July 01, 2018
Estimated Completion Date:
August 01, 2019